IGN 523

Drug Profile

IGN 523

Alternative Names: AML-01; anti-CD98 monoclonal antibody; IGN-523

Latest Information Update: 29 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Igenica
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD98 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 28 Feb 2014 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (NCT02040506)
  • 07 Dec 2013 Preclinical trials in Acute myeloid leukaemia in USA (IV) prior to December 2013
  • 07 Dec 2013 Pharmacodynamics data from preclinical studies in Leukaemia presented at 55th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top